Escient Pharmaceuticals Commences First Human Study for EP262, a Novel Oral Drug Blocking MRGPRX2, Aimed at Treating Eczema.

TOLREMO Initiates Phase 1 Study by Administering TT125-802 to Initial Participant, an Innovative Compound Targeting Transcriptional Resistance in Cancer Treatment.

Aldeyra Therapeutics, Inc. has disclosed that it has received a Complete Response Letter from the FDA regarding the New Drug Application of reproxalap.

NMRA-266, a molecule with selective affinity for enhancing the activity of the M4 muscarinic receptor, is being advanced by Neumora as a potential therapeutic option for the management of schizophrenia as well as various additional mental health conditions.

SpringWorks Therapeutics, Inc., a biopharma company focused on severe rare diseases and cancer, has announced FDA approval for OGSIVEO™ (nirogacestat), an oral gamma secretase inhibitor, to treat progressive desmoid tumors in adults requiring systemic therapy.

Abeona Therapeutics Inc. confirms FDA priority review for their therapy, pz-cel (prademagene zamikeracel), Biologics License Application.

In the Phase III trial for the initial treatment of recurrent/metastatic cervical cancer in all types of patients, Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) has achieved the primary goal of halting disease progression.

Gracell Biotechnologies reveals FDA approval for a Phase 1/2 Clinical Trial IND application concerning FasTCAR-T GC012F, aimed at treating stubborn Systemic Lupus Erythematosus.

TC BioPharm PLC, a clinical-stage biotech company focused on allogeneic gamma-delta T cell cancer therapies, has announced FDA approval for its investigational new drug application to enter a Phase 1B trial for recurrent and refractory Acute Myeloid Leukemia.

The first participant has been dosed in OncoNano Medicine's Phase 1 trial of ONM-501 for individuals with advanced solid cancers and lymphomas.

Acadia Pharmaceuticals Inc. announces Phase 2 trial to test efficacy and safety of ACP-204 for Alzheimer's-related psychosis hallucinations and delusions.

Genmab A/S provided updates on FDA and EMA regulatory progress concerning their bispecific T-cell engaging antibody, epcoritamab, which is administered subcutaneously and under review.